TABLE 3.
Top 30 HIV-1 NNRTI resistance patterns in 2,526 sequences from 2,168 persons with NNRTI resistance, 1997 to 2003
| Mutation pattern | No. (%) of sequencesa | No. of personsa | Cumulative % | Susceptibility to drug (foldn)b
|
||
|---|---|---|---|---|---|---|
| NVP | DLV | EFV | ||||
| K103N | 459 (18.2) | 379 | 18.2 | 4621 | 3421 | 1920 |
| K103N, Y181C | 149 (5.9) | 126 | 24.1 | 4007 | 2507 | 468 |
| Y181C | 116 (4.6) | 100 | 28.7 | 1046 | 306 | 1.06 |
| L100I, K103N | 116 (4.6) | 99 | 33.3 | 789 | 1039 | 2749 |
| K103R | 93 (3.7) | 74 | 36.9 | 0.52 | 0.92 | 0.52 |
| Y188L | 51 (2.0) | 32 | 39.0 | 5005 | 9.05 | 1095 |
| V106I | 50 (2.0) | 46 | 40.9 | 0.33 | 0.13 | 0.23 |
| A98G | 46 (1.8) | 44 | 42.8 | 3.66 | 0.76 | 0.85 |
| K103N, V108I | 44 (1.7) | 41 | 44.5 | 2182 | 652 | 792 |
| K101E, G190A | 44 (1.7) | 33 | 46.2 | 5001 | 2.01 | 1231 |
| K101Q | 38 (1.5) | 35 | 47.7 | 2.21 | 1.41 | 2.11 |
| K101R | 34 (1.3) | 31 | 49.1 | 0.32 | 0.32 | 0.32 |
| K103N, P225H | 34 (1.3) | 28 | 50.4 | 954 | 104 | 1044 |
| K103N, Y181C, G190A | 33 (1.3) | 29 | 51.7 | 2401 | 1901 | 2401 |
| K103N, G190A | 31 (1.2) | 29 | 53.0 | 5001 | 371 | 2131 |
| V108I | 30 (1.2) | 25 | 54.2 | 3.01 | 1.31 | 1.71 |
| Y181C, G190A | 29 (1.1) | 25 | 55.3 | 4903 | 7.23 | 113 |
| K101E | 29 (1.1) | 20 | 56.5 | 121 | 4.91 | 5.01 |
| V179D | 27 (1.1) | 22 | 57.5 | 0.71 | 2.91 | 1.41 |
| K103N, K238T | 26 (1.0) | 24 | 58.6 | 1522 | 252 | 472 |
| K238R | 23 (0.9) | 21 | 59.5 | 0.51 | 0.21 | 0.21 |
| G190A | 22 (0.9) | 21 | 60.3 | 755 | 0.45 | 7.05 |
| K101P, K103N | 22 (0.9) | 16 | 61.2 | 4001 | 2501 | 7001 |
| V108I, Y181C | 20 (0.8) | 18 | 62.0 | 4002 | 402 | 4.92 |
| K101E, Y181C, G190A | 20 (0.8) | 15 | 62.8 | 5472 | 212 | 1032 |
| A98G, K103N | 19 (0.8) | 16 | 63.5 | 1214 | 254 | 324 |
| G190S | 18 (0.7) | 16 | 64.3 | 2063 | 0.43 | 473 |
| K103N, V108I, Y181C | 17 (0.7) | 15 | 64.9 | 4001 | 2501 | 7001 |
| K103N, Y188L | 17 (0.7) | 12 | 65.6 | 6801 | 1901 | 2701 |
| K103N, M230L | 16 (0.6) | 16 | 66.2 | 6902 | 2502 | 3602 |
a
Of the 4,183 persons in this study, 2,168 had 2,526 mutant sequences with 411 different NNRTI mutation patterns. The top 30 patterns accounted for 66.2% of the 2,526 mutant sequences.
b
Median susceptibility results (n-fold) for isolates with matching patterns of drug resistance mutations. The subscript is the number of samples for which susceptibility results are available. Results that are ≥2.5-fold the wild-type control result are shown in bold. Abbreviations: NVP, nevirapine; DLV, delavirdine; EFV, efavirenz.